In vitro activity of quinupristin/dalfopristin and newer quinolones combined with gentamicin against resistant isolates of Enterococcus faecalis and Enterococcus faecium

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 17, Issue 9, 1998, Pages 657-661

  Giamarellos Bourboulis, E J ^a   Sambatakou, H ^b   Grecka, P ^a   Giamarellou, H ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b G GENNIMATAS GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; DALFOPRISTIN PLUS QUINUPRISTIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; QUINOLONE DERIVATIVE; SITAFLOXACIN; SPARFLOXACIN; TROVAFLOXACIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GRAM POSITIVE BACTERIUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

EID: 0032435368     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100960050152     Document Type: Article

References (18)

1. 1. Giamarellou H: Activity of quinolones against gram-positive cocci: clinical features. Drugs (1995) 51, Supplement 2:58-66
2. 2. Bryson HM, Spencer CM: Quinupristin-dalfopristin. Drugs (1996) 52:406-415
3. 3. Eliopoulos GM: In vitro activity of fluoroquinolones against gram-positive bacteria. Drugs (1995) 51, Supplement 2:48-57
4. 4. Shonekan D, Handwerer S, Mildvan D: Comparative in vitro activities of RP59500 (quinupristin/dalfopristin), CL329,998, CL331,002, trovafloxacin, clinafloxacin, teicoplanin and vancomycin against gram-positive bacteria. Journal of Antimicrobial Chemotherapy (1997) 39:405-409
5. 5. Briggs Gooding B, Jones RN: In vitro antimicrobial activity of CP-99,219 a novel azabicyclo-naphthyridone. Antimicrobial Agents and Chemotherapy (1993) 37:349-353
6. 6. Eliopoulos GM, Klimm K, Eliopoulos CT, Ferraro MJ, Moellering RC Jr: In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrobial Agents and Chemotherapy (1993) 37:366-370
7. 7. Coque TM, Singh KY, Murray BE: Comparative in vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against gram-positive cocci. Journal of Antimicrobial Chemotherapy (1996) 37:1011-1016
8. 8. Korten V, Tomayko JF, Murray BE: Comparative in vitro activity of DU-6859a, a new fluoroquinolone agent, against gram-positive cocci. Antimicrobial Agents and Chemotherapy (1994) 38:611-615
9. 9. Giamarellos-Bourboulis EJ, Grecka P, Galani I, Giamarellou H: Comparative in vitro activity and killing effect of trovafloxacin, DU-6859a, levofloxacin and sparfloxacin against Staphylococcus aureus: focus on methicillin-resistant isolates. Clinical Drug Investigation (1997) 14:330-336
10. 10. Pezzlo M: Identification of commonly isolated aerobic gram-positive bacteria. In: Isenberg HD (ed): Clinical microbiology procedures handbook. American Society for Microbiology, Washington DC (1992) pp. 1.20.1-1.20.47
11. 11. Inoue H, Okamoto R, Okubo T, Inoue K, Mitsuhashi S: Comparative in vitro activity of RP59500 against clinical bacterial isolates. Journal of Antimicrobial Chemotherapy (1992) 30, Supplement A: 45-51
12. 12. Jones RN, Johnson DM, Biedenbach DJ, Marshall SA: Activity of two novel fluoroquinolones (DU-6859a and DV-7751 a) tested against glycopeptide-resistant enterococcal isolates. Diagnostic Microbiology and Infectious Disease (1995) 23:123-127
13. 13. Woods GL, Washington JA: Antibacterial susceptibility tests: dilution and disk diffusion methods. In: Murray RP, Baron EJ, Pfaller MA, Tenover FC, Yolken RH (eds): Manual of clinical microbiology. American Society for Microbiology, Washington DC (1995) pp. 1327-1341
14. 14. Hindler J: Tests to assess bactericidal activity. In: Isenberg HD (ed): Clinical microbiology procedures handbook. American Society for Microbiology, Washington DC (1992) pp. 5.16.14-5.16.24
15. 15. Nakashima M, Vematsu T, Kosuge K, Unemura K, Hakusui H, Tanaka M: Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers. Antimicrobial Agents and Chemotherapy (1995) 39:170-174
16. 16. Wise R, Mortiboy D, Child J, Andrews JM: Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219). Antimicrobial Agents and Chemotherapy (1996) 40:47-49
17. 17. Sande MA, Mandell GL: The aminoglycosides. In: Goodman Gilman A, Rall TW, Nies AS, Taylor P (eds): The pharmacological basis of therapeutics. Pergamon Press, New York (1990) pp. 1098-1116
18. 18. Korten V, Erdem I, Murray BE: Bactericidal activity of the fluoroquinolone DU-6859a alone and in combination with other antimicrobial agents against multiresistant enterococci. Diagnostic Microbiology and Infectious Disease (1996) 26:79-85